270 related articles for article (PubMed ID: 9176073)
1. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
Bauditz J; Haemling J; Ortner M; Lochs H; Raedler A; Schreiber S
Gut; 1997 Apr; 40(4):470-4. PubMed ID: 9176073
[TBL] [Abstract][Full Text] [Related]
2. Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease.
MacDonald TT
Gut; 1997 Apr; 40(4):559. PubMed ID: 9176092
[No Abstract] [Full Text] [Related]
3. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Reimund JM; Dumont S; Muller CD; Kenney JS; Kedinger M; Baumann R; Poindron P; Duclos B
Gut; 1997 Apr; 40(4):475-80. PubMed ID: 9176074
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Bauditz J; Wedel S; Lochs H
Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
[TBL] [Abstract][Full Text] [Related]
5. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease.
Bauditz J; Rückert Y; Raedler A; Nikolaus S; Lochs H; Schreiber S
Lancet; 1995 Jun; 345(8962):1445. PubMed ID: 7760641
[No Abstract] [Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
[TBL] [Abstract][Full Text] [Related]
8. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.
Reimund JM; Wittersheim C; Dumont S; Muller CD; Kenney JS; Baumann R; Poindron P; Duclos B
Gut; 1996 Nov; 39(5):684-9. PubMed ID: 9026483
[TBL] [Abstract][Full Text] [Related]
9. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
11. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease.
Song L; Hanlon DW; Chang L; Provuncher GK; Kan CW; Campbell TG; Fournier DR; Ferrell EP; Rivnak AJ; Pink BA; Minnehan KA; Patel PP; Wilson DH; Till MA; Faubion WA; Duffy DC
J Immunol Methods; 2011 Sep; 372(1-2):177-86. PubMed ID: 21821036
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.
Schreiber S; Nikolaus S; Hampe J; Hämling J; Koop I; Groessner B; Lochs H; Raedler A
Lancet; 1999 Feb; 353(9151):459-61. PubMed ID: 9989717
[TBL] [Abstract][Full Text] [Related]
13. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
14. The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease.
van Hogezand RA; Verspaget HW
Drugs; 1998 Sep; 56(3):299-305. PubMed ID: 9777308
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
16. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
[TBL] [Abstract][Full Text] [Related]
17. A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease.
Poturoglu S; Kaymakoglu S; Gurel Polat N; Ibrisim D; Ahishali E; Akyuz F; Badur S; Demir K; Mungan Z
Scand J Clin Lab Invest; 2009; 69(6):696-702. PubMed ID: 19452347
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.
Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG
Aliment Pharmacol Ther; 2004 Jan; 19(1):79-88. PubMed ID: 14687169
[TBL] [Abstract][Full Text] [Related]
19. The protease inhibitor cystatin C down-regulates the release of IL-β and TNF-α in lipopolysaccharide activated monocytes.
Gren ST; Janciauskiene S; Sandeep S; Jonigk D; Kvist PH; Gerwien JG; Håkansson K; Grip O
J Leukoc Biol; 2016 Oct; 100(4):811-822. PubMed ID: 27190304
[TBL] [Abstract][Full Text] [Related]
20. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
